GLP-1s have been a hot topic, now people are raising concerns about the side effects. From loose skin and dull complexions to hair loss and more. Aesthetic ...

The Trump administration faces an arduous task of encouraging states to expand Medicaid coverage of expensive anti-obesity ...

The Centers for Medicare & Medicaid Services (CMS) is developing a pilot program that could change the landscape of obesity ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

The maker of Ozempic and Wegovy obesity drugs said some of the prices could come down, as President Trump called for ...

CMS often withholds coverage for reimbursement, disrupting the natural flow of the market and hindering access to proven ...

Health and Human Services Secretary Robert F. Kennedy Jr said that President Donald Trump calls him up “three or four times a week” to hound him with the same question. At such a critical moment in US ...

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...

Trump administration eyes Medicare and Medicaid coverage for weight loss drugs like Wegovy and Ozempic in a five-year pilot ...